Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2360 West Joppa Road
Joppa Concourse STE 205
Lutherville, MD 21093Phone+1 410-933-7495Fax+1 410-616-7351
Summary
- Dr. Po-Hung Chen is a transplant hepatologist and addiction medicine physician based in Baltimore, MD. He earned his M.D. from Emory University School of Medicine. He also holds a Ph.D. in Clinical Investigation and a Certificate in Public Health Economics from the Johns Hopkins Bloomberg School of Public Health. Dr. Chen completed his residency training in Internal Medicine at Duke University Medical Center. His fellowships in Gastroenterology/Hepatology and Transplant Hepatology were at Johns Hopkins University, where he has been a faculty member since 2015. His work focuses on conditions such as alcohol-associated liver disease, alcohol use disorder, metabolic dysfunction-associated steatotic liver disease, and viral hepatitides. He has contributed to multiple publications on liver disease and substance use disorder and has participated in clinical trials related to liver transplantation and cholangitis. He has received several honors, including membership in the Delta Omega Honorary Society in Public Health and a Faculty Teaching Award from Johns Hopkins University.
Education & Training
- Johns Hopkins Bloomberg School of Public HealthPh.D., Clinical Investigation, 2018 - 2023
- Johns Hopkins Bloomberg School of Public HealthCertificate, Public Health Economics, 2018 - 2021
- Johns Hopkins UniversityFellowship, Transplant Hepatology, 2014 - 2015
- Johns Hopkins UniversityFellowship, Gastroenterology, 2010 - 2013
- Duke University HospitalResidency, Internal Medicine, 2007 - 2010
- Emory University School of MedicineClass of 2007, M.D.
- Duke UniversityB.S., Biology, 1999 - 2003
- Duke UniversityA.B., Music, 1999 - 2003
Certifications & Licensure
- MD State Medical License 2013 - 2026
- NC State Medical License 2007 - 2010
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
- American Board of Preventive Medicine Addiction Medicine
Awards, Honors, & Recognition
- Membership Delta Omega Honorary Society in Public Health, 2023
- Clinical Research Leadership Program American College of Gastroenterology, 2023
- Outstanding Contribution Award Journal of Clinical and Translational Hepatology, 2019-2020
- Join now to see all
Clinical Trials
- Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Start of enrollment: 2012 Sep 01
Roles: Contact
- Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH Start of enrollment: 2020 Nov 20
Publications & Presentations
PubMed
- Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease.Derek D Satre, Dhweeja Dasarathy, Steven L Batki, Michael J Ostacher, Hannah R Snyder
Alimentary Pharmacology & Therapeutics. 2025-02-01 - Recipients of Early Liver Transplants for Alcohol-Related Liver Disease May Reside in Areas With Lower Social Vulnerability.James Flanary, Elizabeth A King, Fnu Baimaji, Alexandra T Strauss, Nicole Welch
Gastro Hep Advances. 2025-01-01 - Convergence of Alcohol Consumption and Dietary Quality in US Adults Who Currently Drink Alcohol: An Analysis of Two Core Risk Factors of Liver Disease.Peng-Sheng Ting, Wei-Ting Lin, Suthat Liangpunsakul, Madeline Novack, Chiung-Kuei Huang
Nutrients. 2024-11-13
Press Mentions
- During pandemic, hospitals see rise in alcohol-related liver diseaseJuly 17th, 2021
- 5 Surprising Things to Know About Fatty Liver DiseaseMay 6th, 2022
- The U.S.’s alcohol-induced death rate rose sharply in the pandemic’s first yearNovember 4th, 2022
- Join now to see all
Grant Support
- Project 2-Optimization of Post-Transplant care via Biomarkers and Behavioral InterventionsNational Institute on Alcohol Abuse and Alcoholism2019–2029
- Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Data Coordinating CenterNational Institute of Diabetes and Digestive and Kidney Diseases2022–2025
- Candidate Selection for Liver Transplantation in Patients with Alcohol-related Liver DiseaseNational Institute on Alcohol Abuse and Alcoholism2020–2025
- Development of an Interactive Bioethics Training Module for Healthcare ProvidersNational Institute on Alcohol Abuse and Alcoholism2023–2024
- The Impacts of Early Liver Transplantation and Sustained Abstinence on the Natural History of Severe Alcoholic Hepatitis – A Survival Benefit StudyGilead Sciences Research Scholars Program2019–2024
- Candidate Selection for Liver Transplantation in Patients with Alcohol-related Liver DiseaseJohns Hopkins University School of Medicine2020
- The Burden of Crohn’s Disease in Medicaid and Medicare PopulationsThe Helmsley Charitable Trust2019–2020
- Recurrence of non-alcoholic fatty liver disease after liver transplantation: incidence, risk factors, and implicationsJohns Hopkins Institute for Clinical and Translational Research / National Center for Advancing Translational Sciences2017–2019
- Estimating changes in liver fibrosis over time in patients with chronic viral hepatitis with transient elastography (i.e., FibroScan)Johns Hopkins Medicine / Kaiser Permanente Research Collaboration Committee2017–2018
- The role of moderate alcohol consumption in nonalcoholic fatty liver diseaseABMRF/The Foundation for Alcohol Research2013–2015
Committees
- Member, ACG Practice Parameters Committee 2024 - Present
- Member, ACG Lauren Gerson GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) Program 2024 - Present
- Member, ACG Research Committee 2023 - 2024
- Member, AASLD Practice Guidelines Committee 2022 - 2024
- Steering Committee, AASLD Alcohol-associated Liver Disease Special Interest Group 2021 - 2023
- Member, AASLD Continuing Medical Education Committee 2019 - 2021
Professional Memberships
- Fellow
- Member
- American Association for the Study of Liver Diseases - AASLDMember
- Research Society on Alcoholism - RSAMember
- Delta Omega Honorary Society in Public HealthMember
- International Liver Transplantation Society - ILTSMember
- Member
Other Languages
- Chinese (Mandarin), Taiwanese
External Links
- Johns Hopkins Medicinehttps://profiles.hopkinsmedicine.org/provider/Victor+Chen/2703694
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: